Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q4 FY2020 Earnings Presentation
14 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Jun 25, 2020
Slide 1: Cover letter to National Stock Exchange of India
June 25, 2020 National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai 400 051 Stock Symbol: JBCHEPHARM Dear Sir, Sub: Presentation Enclosed is investor presentation on consolidated performance during quarter and year ended on March 31, 2020. This letter is bein
Slide 2: Earnings Presentation Q4-FY20/FY20
JB Chemicals and Pharmaceuticals Limited EARNINGS PRESENTATION Q4-FY20/FY20
Slide 3: Value Proposition
Value Proposition High Ranking Consistent Dividend Track Record JBCPL is among the top 30 pharmaceutical Consistent dividend policy with three successful companies in India buybacks in last 3 years Major Brands Strong Cash Flows JBCPL’s 4 brands are amongst top 300 IPM brands in India Consistent Ope
Slide 4: Company Overview
Company Overview • J.B Chemicals and Pharmaceuticals Ltd. (JBCPL) was incorporated in 1976 under the chairmanship of Mr. J.B Mody. • Over the past four decades JBCPL has established major brands not just in India, but also globally, with presence in more than 20 other countries. • The company is wel
Slide 5: Q4-FY20 and FY20 Financial Overview
Q4-FY20 and FY20 Financial Overview 4
Slide 6: Q4-FY20/FY20 Financial Highlights
Q4-FY20/FY20 Financial Highlights Q4-FY20 Consolidated Performance: • Revenue from Operations: INR 4,436 Mn • EBITDA : INR 917 Mn • EBITDA Margins: 20.67% • Net Profit: INR 501 Mn • PAT Margins: 11.29% • Diluted EPS: INR 6.30 per share FY20 Consolidated Performance: • Revenue from Operations: INR 17
Slide 7: Q4-FY20/FY20 Segmental Performance
Q4-FY20/FY20 Segmental Performance Domestic Formulations Branded Generic Export US Generic 7,357 5,308 1,792 6,225 4,825 1,423 1,491 1,847 1,285 1,382 432 319 Q4-FY19 vs Q4-FY20 FY19 vs FY20 Q4-FY19 vs Q4-FY20 FY19 vs FY20 Q4-FY19 vs Q4-FY20 FY19 vs FY20 Contract Manufacturing API Contrast Media 1,6
Slide 8: Q4-FY20 Operational Highlights
Q4-FY20 Operational Highlights v Domestic formulation business registered growth of 24% YoY v Export business got affected due to lockdown during March end and declined by 6% YoY v Growth in ANDA business got effected due to API supply issue at vendor location v Margin improvement due to better prod
Slide 9: Q4-FY20 Consolidated Income Statement
Q4-FY20 Consolidated Income Statement PARTICULARS (INR Mn) Q4-FY20 Q4-FY19 Y-o-Y Operational Revenue 4,436 4,189 5.9% Total Expenses 3,519 3,534 (0.4)% EBITDA 917 655 40.0% EBITDA Margins (%) 20.67% 15.64% 503 Bps Other Income 32 157 (79.6)% Depreciation and Amortisation Expense 174 116 50.0% Financ
Slide 10: FY20 Consolidated Income Statement
FY20 Consolidated Income Statement PARTICULARS (INR Mn) FY20 FY19 Y-o-Y Operational Revenue 17,747 16,432 8.0% Total Expenses 13,972 13,374 4.5% EBITDA 3,775 3,058 23.4% EBITDA Margins (%) 21.27% 18.61% 266 Bps Other Income 507 414 22.5% Depreciation and Amortisation Expense 663 556 19.2% Finance Co
Slide 11: Historical Consolidated Income Statement (Ind-AS)
Historical Consolidated Income Statement (Ind-AS) PARTICULARS (INR Mn) FY18 FY19 FY20 Operational Revenue 14,130* 16,432 17,747 Total Expenses 11,956 13,374 13,972 EBITDA 2,174 3,058 3,775 EBITDA Margins (%) 15.39% 18.61% 21.27% Other Income 371 414 507 Depreciation and Amortisation Expense 570 556
Slide 12: Consolidated Balance Sheet (Ind-AS)
Consolidated Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY19 FY20 PARTICULARS (INR Mn) FY19 FY20 Equities & Liabilities Assets (A) Share Capital 160 155 Non-current Assets 7,408 7,409 (B) Other Equity 14,641 14,200 (A) Property, Plant and Equipment 5,444 5,680 Equity attributable to equity holders
Slide 13: Capital Market
Capital Market 80% 60% 40% 20% 0% -20% -40% 9 9 19 19 19 20 20 9 9 9 9 9 9 9 9 9 20 20 19 19 0 0 0 9 9 19 19 r-1 r-1 r-1 t-1 t-1 -2 -2 -2 -1 -1 1 1 l-1 l-1 v-1 v-1 n- n- c- c- n- n- g- g- p- p- p- b- b- ar ar ar ay ay Ju Ju Oc Oc Ap Ap Ap De De No No Ju Ju Au Au Ja Ja Se Se Se Fe Fe M M M M M JBCPL
Slide 14: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
JB Chemicals & Pharmaceuticals — Q4 FY2020 Earnings Presentation on 6ix